Discover the top 29 companies transforming the point of care diagnostics market, including Abbott, Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, and other industry leaders. Backed by a market projected to grow from $15.05B to $22.63B by 2029 at a CAGR of 8.5%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.
Download PDF Brochure:“Click Here”
Spotlights on the Industry’s Top Point of Care Diagnostics Companies
Abbott
Abbott is a global healthcare leader and a dominant player in the in vitro diagnostics (IVD) market, with a presence in 95 countries. The company offers a comprehensive portfolio across core laboratory, molecular, and point-of-care diagnostics, featuring flagship platforms such as Alinity and ARCHITECT. Abbott’s commitment to innovation is highlighted by its rapid molecular system, ID NOW, and the i-STAT handheld blood analyzers. Strategically, the company continues to expand its geographic reach and enhance its diagnostic capabilities through the development of high-throughput systems and point-of-care solutions for infectious diseases, cardiology, and routine screening.
Siemens Healthineers AG
Siemens Healthineers AG is a leading global medical technology company operating through four primary segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Diagnostics segment provides a broad range of in vitro diagnostic products, services, and solutions to healthcare providers in over 180 countries. With a significant investment in R&D, the company focuses on launching technologically advanced systems for clinical chemistry, immunoassay, and molecular testing. Siemens Healthineers leverages its vast installed base of over 600,000 systems to drive recurring revenue through consumables and services, while integrating AI-driven digital tools to optimize laboratory workflows and clinical decision-making.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd is a global pioneer and the leading provider of in vitro diagnostics (IVD) worldwide. Through its Roche Diagnostics division, the company offers an industry-leading portfolio covering molecular diagnostics, clinical chemistry, immunoassays, tissue diagnostics, and point-of-care testing. Roche’s strategy focuses on personalized healthcare, integrating diagnostic insights with pharmaceutical treatments to improve patient outcomes. The company continues to dominate the IVD landscape through major research investments and strategic acquisitions, such as GenMark Diagnostics and TIB Molbiol, while maintaining market-leading platforms like the cobas series for centralized laboratory testing.
Danaher
Danaher is a leading global life sciences and diagnostics innovator with a robust presence in the in vitro diagnostics (IVD) market through its specialized operating companies like Beckman Coulter, Cepheid, and Leica Biosystems. The company provides a comprehensive suite of clinical tools, consumables, reagents, and software used for disease diagnosis and treatment planning in over 100 countries. Danaher leverages its vast global manufacturing network and the Danaher Business System (DBS) to drive operational excellence and continuous innovation. Recent strategic moves, including the acquisition of Abcam plc, have further strengthened its capabilities in diagnostics and life sciences, reinforcing its position as a top-tier global provider.
QuidelOrtho Corporation
QuidelOrtho Corporation is a premier global provider of innovative in vitro diagnostic (IVD) solutions, formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The company specializes in point-of-care testing, clinical chemistry, immunoassay, and molecular diagnostics, offering a wide range of products for infectious diseases, cardiology, and transfusion medicine. By combining Quidel’s expertise in rapid testing with Ortho’s leadership in clinical laboratories and blood banking, QuidelOrtho provides scalable diagnostic tools that improve workflow efficiency and patient care across the clinical spectrum.
BD
BD (Becton, Dickinson and Company) is a leading global medical technology company that advances the world of health by improving medical discovery, diagnostics, and the delivery of care. In the in vitro diagnostics (IVD) market, BD Life Sciences provides an extensive array of solutions for specimen collection, microbiology, and molecular diagnostics. The company is recognized for its innovative BD MAX and BD COR systems, which automate laboratory processes to provide faster, more accurate results for infectious diseases and women’s health. BD’s global scale and focus on integrated diagnostic workflows make it a vital partner for clinical laboratories and healthcare systems worldwide.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is the world leader in serving science, providing a comprehensive range of analytical instruments, reagents, and consumables for the in vitro diagnostics (IVD) market. Through its Specialty Diagnostics segment, the company offers advanced solutions for clinical chemistry, immunoassays, microbiology, and transplant diagnostics. Thermo Fisher is a key player in molecular diagnostics and next-generation sequencing, enabling precision medicine and rapid infectious disease testing. Its extensive distribution network and commitment to R&D innovation allow it to support clinical laboratories and research institutions in improving diagnostic accuracy and efficiency globally.
BioMérieux
BioMérieux is a world leader in the field of in vitro diagnostics (IVD), specializing in the diagnosis of infectious diseases. Based in France, the company provides diagnostic solutions (reagents, instruments, and software) that determine the source of disease and contamination to improve patient health and ensure consumer safety. BioMérieux is particularly renowned for its leadership in microbiology, offering flagship platforms like VITEK for bacterial identification and antibiotic susceptibility testing, and FilmArray for rapid syndromic molecular testing. The company’s focus on antimicrobial stewardship and rapid diagnostics positions it at the forefront of global public health efforts.
Biosynex SA
Biosynex SA is a prominent French laboratory specializing in the design, manufacture, and distribution of rapid diagnostic tests (RDTs). The company provides a diverse range of in vitro diagnostic (IVD) solutions for healthcare professionals and home use, covering areas such as infectious diseases, women’s health, and cardiology. Biosynex has expanded its market presence through strategic acquisitions and a strong focus on point-of-care testing, enabling faster medical decision-making. Its commitment to innovation in decentralized diagnostics supports the growing demand for accessible and reliable testing in both clinical and community settings.
EKF Diagnostics Holdings PLC
EKF Diagnostics Holdings PLC is a global medical technology company specializing in point-of-care (POC) diagnostics and central laboratory products. The company’s portfolio includes market-leading analyzers for hemoglobin and glucose testing, used extensively in physician offices, clinics, and blood banks worldwide. EKF also provides specialized services in contract manufacturing and enzyme production for the broader IVD industry. With a focus on delivering cost-effective and reliable diagnostic tools, EKF supports the management of chronic conditions such as diabetes and anemia, contributing to improved patient outcomes in both developed and emerging markets.
Trinity Biotech
Trinity Biotech is a specialized diagnostic company that develops, manufactures, and markets in vitro diagnostic (IVD) products for the clinical laboratory and point-of-care (POC) segments. The company’s product range includes diagnostic tests for infectious diseases, diabetes, and autoimmune disorders. Trinity Biotech is recognized for its expertise in Hemoglobin A1c testing and its range of rapid tests for HIV and other sexually transmitted infections. By providing accurate and easy-to-use diagnostic solutions, the company supports healthcare providers in screening and monitoring prevalent health conditions globally.
Werfen
Werfen is a major global player in the in vitro diagnostics (IVD) market, specializing in three key areas: Hemostasis, Acute Care Diagnostics, and Autoimmunity. The company provides integrated systems, reagents, and data management solutions that enable clinicians to make critical decisions in hospital and laboratory settings. Werfen is highly regarded for its leadership in Hemostasis testing and its innovative GEM Premier platforms for blood gas analysis. Through its commitment to R&D and strategic focus on specialized diagnostics, Werfen enhances clinical workflows and patient care in high-acuity environments worldwide.
Nova Biomedical
Nova Biomedical is a global leader in the development and manufacture of advanced technology blood testing analyzers. In the in vitro diagnostics (IVD) market, the company is primarily known for its high-performance blood gas analyzers and point-of-care (POC) meters for glucose, lactate, and creatinine testing. Nova’s Allegro and Stat Profile platforms are widely used in hospitals and clinics for rapid, accurate assessment of critically ill patients. With a strong emphasis on sensor technology and clinical accuracy, Nova Biomedical provides essential tools for emergency medicine, intensive care, and chronic disease management.
Sekisui Diagnostics
Sekisui Diagnostics is a global provider of diverse in vitro diagnostic (IVD) products and services, serving clinical laboratories and point-of-care (POC) settings. The company’s portfolio includes clinical chemistry reagents, coagulation tests, and rapid diagnostic kits for infectious diseases such as influenza and strep throat. Sekisui is also a leading manufacturer of specialty enzymes for the global diagnostic industry. By focusing on quality, reliability, and innovative product development, Sekisui Diagnostics helps healthcare providers deliver accurate results that improve patient management and operational efficiency.
Boditech Med Inc.
Boditech Med Inc. is a South Korea-based leader in point-of-care (POC) diagnostics, specializing in the development of innovative immunoassay platforms and reagents. The company’s ichroma and AFIAS systems provide rapid and accurate testing for various clinical markers, including cardiac, hormonal, and infectious diseases. Boditech Med focuses on providing decentralized diagnostic solutions that are easy to use in diverse healthcare environments, from primary care clinics to large hospitals. Its commitment to R&D and global market expansion has established it as a key provider of accessible diagnostic technology worldwide.
Grifols, S.A.
Grifols, S.A. is a global healthcare company and a leader in the production of plasma-derived medicines and transfusion medicine diagnostics. In the in vitro diagnostics (IVD) market, Grifols provides advanced solutions for blood screening and compatibility testing, ensuring the safety of the global blood supply. Its portfolio includes automated systems and reagents for immunohematology and molecular testing, such as the Procleix assays for detecting infectious diseases in donor blood. Grifols’ focus on innovation and safety makes it a critical partner for blood banks and clinical laboratories involved in transfusion and transplant medicine.
Lifescan IP Holdings, LLC
LifeScan IP Holdings, LLC is a global leader in blood glucose monitoring and a pioneer in diabetes management technology. The company’s flagship OneTouch brand provides a range of blood glucose meters, test strips, and digital health tools used by millions of people with diabetes worldwide. LifeScan focuses on delivering simple, accurate, and connected diagnostic solutions that empower patients to self-manage their condition and help healthcare providers optimize therapy. By integrating diagnostic data with mobile platforms, LifeScan continues to drive innovation in the personalized management of chronic metabolic diseases.
PTS Diagnostics
PTS Diagnostics is a global provider of point-of-care (POC) diagnostic solutions, specializing in tools for the management of cardiometabolic diseases. The company is best known for its CardioChek analyzers, which provide rapid, lab-accurate testing for lipid profiles and glucose levels from a simple fingerstick. PTS Diagnostics also offers the A1CNow system for monitoring long-term blood sugar control in diabetic patients. With a focus on portability and ease of use, PTS Diagnostics enables healthcare professionals to conduct vital screenings and interventions in community and clinical settings, promoting early detection and better health outcomes.
Eurolyser Diagnostica GmbH
Eurolyser Diagnostica GmbH is an Austrian-based manufacturer of high-precision point-of-care (POC) diagnostic systems for both human and veterinary medicine. The company specializes in the development of compact, automated analyzers and a broad menu of innovative tests for biomarkers such as CRP, HbA1c, and Vitamin D. Eurolyser focuses on providing “lab-quality” results at the point of care, enabling immediate medical decisions and improved patient management. Its commitment to technological excellence and user-friendly design makes it a preferred choice for small laboratories and physician offices globally.
Response Biomedical
Response Biomedical is a specialized diagnostic company that develops and manufactures rapid, quantitative point-of-care (POC) tests for critical care and infectious disease management. The company’s flagship RAMP platform uses proprietary fluorescence immunoassay technology to provide fast and accurate results for markers such as Troponin I, NT-proBNP, and Procalcitonin. Response Biomedical focuses on empowering clinicians with timely diagnostic information in emergency departments and other high-pressure clinical settings, supporting faster triage and improved patient outcomes through reliable near-patient testing.
Alfa Scientific Designs, Inc.
Alfa Scientific Designs, Inc. is a California-based leader in the development and manufacture of rapid in vitro diagnostic (IVD) tests. The company specializes in innovative point-of-care (POC) solutions, utilizing its proprietary Driven Flow technology to improve the speed and accuracy of lateral flow assays. Alfa’s extensive product line covers drug of abuse testing, infectious diseases, women’s health, and cardiac markers. With a commitment to high-quality US-based manufacturing and R&D, Alfa Scientific Designs provides reliable diagnostic tools for clinical, forensic, and home use markets worldwide.
BTNX Inc.
BTNX Inc. is a Canadian biotechnology company specializing in the development and distribution of rapid diagnostic tests for various medical applications. The company provides a wide range of in vitro diagnostic (IVD) solutions, including point-of-care (POC) tests for infectious diseases, drugs of abuse, and fertility. BTNX is recognized for its ability to quickly bring innovative diagnostic products to market, supporting public health needs and clinical screening. Its focus on providing cost-effective and easy-to-use testing kits makes it a valuable supplier for healthcare professionals and laboratories globally.
Ascensia Diabetes Care Holdings AG
Ascensia Diabetes Care Holdings AG is a global specialist in diabetes care, dedicated to helping people living with diabetes manage their condition through innovative diagnostic solutions. The company is the manufacturer of the renowned CONTOUR range of blood glucose monitoring systems, known for their accuracy and user-friendly features. Ascensia also partners with technology leaders to provide continuous glucose monitoring (CGM) systems, such as Eversense. By focusing on high-quality diagnostics and digital health integration, Ascensia empowers patients and healthcare providers to make informed decisions for better diabetes management.
Fluxergy
Fluxergy is a specialized medical technology company that provides a multimodal point-of-care (POC) diagnostic platform designed for rapid and versatile testing. The Fluxergy system integrates molecular, immunochemical, and cytology testing capabilities into a single, compact analyzer, enabling diverse diagnostic applications from infectious disease detection to wellness monitoring. By leveraging advanced microfluidics and sensor technology, Fluxergy aims to make sophisticated laboratory-grade testing more accessible in decentralized settings, supporting faster medical interventions and more efficient healthcare delivery.
Precision Biosensor, Inc.
Precision Biosensor, Inc. is an innovative diagnostic company based in South Korea, specializing in the development of high-sensitivity point-of-care (POC) testing systems. The company’s Exdia platforms utilize time-resolved fluorescence (TRF) technology to provide quantitative results for a wide range of clinical markers, including cardiac, infectious disease, and inflammation indicators. Precision Biosensor focuses on bridging the gap between central laboratory accuracy and the convenience of POC testing, providing healthcare professionals with reliable tools for rapid clinical decision-making and patient monitoring.
Acon Laboratories, Inc.
Acon Laboratories, Inc. is a global manufacturer of high-quality diagnostic and medical devices, offering a broad portfolio of in vitro diagnostic (IVD) products across several segments. The company provides rapid diagnostic tests, clinical chemistry reagents, and point-of-care (POC) systems for diabetes management and infectious disease screening. Acon is recognized for its ability to produce reliable, cost-effective diagnostic tools on a large scale, supporting healthcare systems and consumers in over 130 countries. Its commitment to continuous innovation and manufacturing excellence ensures the availability of essential diagnostic solutions for diverse medical needs.
Menarini Diagnostics S.r.l
Menarini Diagnostics S.r.l, part of the Menarini Group, is a prominent European provider of diagnostic solutions for clinical laboratories and point-of-care (POC) settings. The company specializes in diabetes management, hematology, and clinical chemistry, offering a range of automated analyzers and specialized reagents. Menarini is also a leader in the development of innovative tools for pathology and cell-based diagnostics. By combining advanced technology with a strong service network, Menarini Diagnostics supports healthcare professionals in delivering accurate and timely results, enhancing the quality of patient care across various medical specialties.
OraSure Technologies, Inc.
OraSure Technologies, Inc. is a leader in the development and manufacture of point-of-care (POC) diagnostic tests and specimen collection devices. The company is widely recognized for its innovative oral fluid testing solutions, such as the OraQuick rapid tests for HIV, HCV, and Ebola, which provide results in minutes without the need for blood samples. OraSure also provides advanced tools for microbiome research and genomic testing through its subsidiaries. By focusing on non-invasive and easy-to-use diagnostic products, OraSure empowers individuals to know their status and enables healthcare providers to conduct effective screenings in diverse settings.
Mankind Pharma
Mankind Pharma is one of India’s largest and fastest-growing pharmaceutical companies, with an expanding presence in the in vitro diagnostics (IVD) market. Through its diagnostics division, Mankind provides a range of affordable and reliable diagnostic products, including rapid test kits for infectious diseases, pregnancy, and chronic condition monitoring. The company leverages its extensive distribution network and strong brand presence to make essential diagnostic tools accessible to a broad population. Mankind’s strategic focus on affordability and quality supports the development of healthcare infrastructure and improved disease screening in emerging markets.
Download PDF Brochure:“Click Here”
